HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM.

ABSTRACT:

Objective

Anal cancer precursor lesions high-grade anal intraepithelial neoplasia (HGAIN) are highly prevalent among HIV+ MSM. Treatment of HGAIN is frustrated by high recurrence rates. We investigated the efficacy of the quadrivalent human papillomavirus (qHPV) vaccine as posttreatment adjuvant in preventing HGAIN recurrence in HIV+ MSM.

Design

Randomized, double-blind, placebo-controlled, multicentre trial.

Setting

Three HIV outpatient clinics in Amsterdam, the Netherlands.

Subjects

HIV+ MSM with CD4+ cell count more than 350 cells/μl, biopsy-proven intra-anal HGAIN successfully treated in the past year, and lesions still in remission at enrolment, as assessed by high-resolution anoscopy (HRA).

Intervention

Participants were randomized to three doses o

SUBMITTER: Gosens KCM 

PROVIDER: S-EPMC8373452 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature